Antisicóticos alcanzaron $24 billiones de ventas en 2010

Hoy, que comienza en Oviedo/Asturias el XV Congreso Nacional de Psiquiatría...

Excelencia? o
medicamentalización?

ROCKVILLE, MD — MarketResearch.com has announced the addition of the new report "The CNS Market Outlook to 2016," to their collection of Pharmaceuticals market reports.

The central nervous system (CNS), made up of the brain and spinal cord, controls individuals' actions, thoughts and emotions. These functions are controlled by neurotransmitters. Antidepressants increase the brain's concentration of various neurotransmitters. Generally speaking, antipsychotic medications work by blocking a specific subtype of the dopamine receptor, referred to as the D2 receptor. Atypical antipsychotics, a second generation of antipsychotics, block D2 receptors as well as a specific subtype of serotonin receptor, the 5HT2A receptor.

This report provides comprehensive coverage of the global CNS market, incorporating disease overview, epidemiological analyses of the major indications, and market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading CNS brands are assessed and five of the market's leading players are profiled.

Antipsychotics were the largest CNS drug class with $24.2bn sales, a 33.9% share of the market in 2010. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016.

Imminent patent expiries for major brands have resulted in companies investigating new indications and re-formulation strategies to extend patents and safeguard revenue streams. Companies have also begun to manufacture and market generic versions of their products. (Ver)